ストックスクリーナーアプリを入手
20.56
3.56%
-0.76
プレマーケット:
20.50
-0.06
-0.29%
前日終値:
$21.32
開ける：
$21.07
24時間の取引高:
8.08M
Relative Volume:
1.01
時価総額：
$14.04B
収益：
$125.68M
当期純損益:
$4.81B
株価収益率:
3.6389
EPS:
5.65
ネットキャッシュフロー:
$-781.21M
1週間 パフォーマンス:
-0.05%
1か月 パフォーマンス:
+26.84%
6か月 パフォーマンス:
+91.08%
1年 パフォーマンス:
+72.05%
1日の値動き範囲:
$20.54
$21.23
1週間の範囲:
$19.79
$21.35
52週間の値動き範囲:
$8.73
$21.35
Roivant Sciences Ltd Stock (ROIV) Company Profile
ROIV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
20.56 | 14.83B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.99 | 71.65B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.97 | 59.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.73 | 54.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
368.36 | 41.77B | 4.98B | 69.59M | 525.67M | 0.5197 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-02 | 開始されました | Citigroup | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-01-05 | 開始されました | Piper Sandler | Overweight |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-17 | 開始されました | Guggenheim | Buy |
| 2023-06-08 | 開始されました | BofA Securities | Neutral |
| 2022-10-27 | 開始されました | JP Morgan | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 開始されました | Goldman | Buy |
| 2021-11-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-28 | 開始されました | Citigroup | Buy |
| 2021-10-26 | 開始されました | Cowen | Outperform |
| 2021-10-26 | 開始されました | Jefferies | Buy |
| 2021-10-26 | 開始されました | Truist | Buy |
すべてを表示
Roivant Sciences Ltd (ROIV) 最新ニュース
Guggenheim raises Roivant Sciences stock price target to $25 on pipeline progress - Investing.com India
Is Roivant Sciences Ltd. (87S) stock a momentum leaderOptions Play & Low Volatility Stock Recommendations - newser.com
Best data tools to analyze Roivant Sciences Ltd. stock2025 Institutional Moves & Growth Focused Investment Plans - newser.com
How to forecast Roivant Sciences Ltd. trends using time seriesPortfolio Gains Summary & Reliable Intraday Trade Alerts - newser.com
Can Roivant Sciences Ltd. (87S) stock survive global slowdownJuly 2025 Earnings & Fast Entry and Exit Trade Plans - newser.com
Can Roivant Sciences Ltd. (87S) stock resist broad market declinesDip Buying & Fast Gain Stock Tips - newser.com
Real time breakdown of Roivant Sciences Ltd. stock performanceBull Run & Smart Allocation Stock Tips - newser.com
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced (NASDAQ:ROIV) - Seeking Alpha
Can Roivant Sciences Ltd. rally from current levelsJobs Report & Daily Momentum Trading Reports - newser.com
Roivant Sciences (ROIV): Evaluating Valuation After Earnings, Pipeline Wins, and Legal Milestone - simplywall.st
Is Roivant Sciences Ltd. (87S) stock safe for risk averse investorsTrade Analysis Summary & Real-Time Market Sentiment Alerts - newser.com
Roivant Sciences Hits New 52-Week High of $20.77, Up 94.9% Year-to-Date - Markets Mojo
Citigroup Maintains Roivant Sciences (ROIV) Buy Recommendation - Nasdaq
Looking Into Roivant Sciences Ltd's Recent Short Interest - Benzinga
Roivant Sciences at Guggenheim Conference: Strategic Pipeline Focus - Investing.com India
Transcript : Roivant Sciences Ltd. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-11-2025 08 - MarketScreener
Roivant Sciences at Guggenheim Conference: Strategic Pipeline Focus By Investing.com - Investing.com Australia
Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2026 Earnings Call Transcript - Insider Monkey
Will Roivant Sciences Ltd. stock gain from government policies2025 Trade Ideas & Daily Profit Focused Stock Screening - newser.com
ROIV Crosses Above Average Analyst Target - Nasdaq
Leerink Partners raises Roivant Sciences stock price target to $29 on model extension - Investing.com Australia
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Roivant Sciences Reports Q2 2025 Financial Results - TipRanks
ROIV SEC FilingsRoivant Sciences 10-K, 10-Q, 8-K Forms - Stock Titan
Is Roivant Sciences Ltd. (87S) stock prepared for digital transition2025 Earnings Impact & High Accuracy Investment Signals - newser.com
Will Roivant Sciences’ (ROIV) Slowing Revenue Growth Shape Its Long-Term Innovation Story? - Yahoo Finance
Roivant Sciences earnings beat by $0.15, revenue fell short of estimates - Investing.com South Africa
Roivant Sciences (ROIV) PT Raised to $26 at Citi - StreetInsider
Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Call Highlights: Strong Financial Position and ... By GuruFocus - Investing.com Canada
Roivant Sciences Q2 2026 Earnings Call Transcript - MarketBeat
Roivant Sciences Ltd. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ROIV) 2025-11-10 - Seeking Alpha
Earnings call transcript: Roivant Sciences Q2 2026 beats EPS forecast - Investing.com
Earnings call transcript: Roivant Sciences Q2 2026 beats EPS forecast By Investing.com - Investing.com Australia
Roivant Sciences Ltd. (ROIV) Tops Q2 EPS by 15c - StreetInsider
Roivant Sciences' Fiscal Q2 Net Loss Narrows, Revenue Falls - MarketScreener
Roivant Sciences Ltd. SEC 10-Q Report - TradingView
[8-K] Roivant Sciences Ltd. Reports Material Event | ROIV SEC FilingForm 8-K - Stock Titan
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update - The Manila Times
Roivant Sciences Ltd (ROIV) 財務データ
収益
当期純利益
現金流量
EPS
0.35%
0.75%
大文字化:
|
ボリューム (24 時間):